Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Søren Cold

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)Jørn Andersen, Claus Kamby, Bent Ejlertsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Effect of obesity on prognosis after early-stage breast cancerMarianne Ewertz, Maj-Britt Jensen, Katrín Á Gunnarsdóttir, et al.
Oncotarget|March 7, 2018
Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancerInes Block, Mark Burton, Kristina P Sørensen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 12, 2022
Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled TrialGiorgia Perri, Tom R Hill, John C Mathers, et al.
Cancer Medicine|April 27, 2024
Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastasesInes Block, Mark Burton, Kristina P Sørensen, et al.
Cancers|October 13, 2021
Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast CancerThi T N Do, Ines Block, Mark Burton, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2007
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancerBent Ejlertsen, Henning T Mouridsen, Maj-Britt Jensen, et al.
Rapid Communications in Mass Spectrometry : RCM|May 26, 2005
Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometryAnne K Callesen, Shabaz Mohammed, Jakob Bunkenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ TrialMaj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative GroupDorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)Jørn Andersen, Claus Kamby, Bent Ejlertsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Effect of obesity on prognosis after early-stage breast cancerMarianne Ewertz, Maj-Britt Jensen, Katrín Á Gunnarsdóttir, et al.
Oncotarget|March 7, 2018
Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancerInes Block, Mark Burton, Kristina P Sørensen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 12, 2022
Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled TrialGiorgia Perri, Tom R Hill, John C Mathers, et al.
Cancer Medicine|April 27, 2024
Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastasesInes Block, Mark Burton, Kristina P Sørensen, et al.
Cancers|October 13, 2021
Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast CancerThi T N Do, Ines Block, Mark Burton, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2007
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancerBent Ejlertsen, Henning T Mouridsen, Maj-Britt Jensen, et al.
Rapid Communications in Mass Spectrometry : RCM|May 26, 2005
Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometryAnne K Callesen, Shabaz Mohammed, Jakob Bunkenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ TrialMaj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2011
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative GroupDorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, et al.
Pageof 5